Back

I3LUNG: Clinical Validation of a Multimodal AI Tool to Support Immunotherapy Decisions in NSCLC

2026-01-22 oncology Title + abstract only
View on medRxiv
Show abstract

Despite a decade of immunotherapy, treatment selection in non-small cell lung cancer (NSCLC) still relies on subgroup analyses and clinical scores. I3LUNG (NCT05537922) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based trial, enrolling 2365 patients. We integrated real-world clinical data (RWD), computed tomography (CT) images, digital pathology (DP), and genomics (G) into machine learning early-fusion (MLEF) and deep-learning intermediate-fusion ...

Predicted journal destinations